ATAC-Array Chromatin Profiling for PDAC Recurrence Stratification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatment protocols for pancreatic ductal adenocarcinoma (PDAC) lack the ability to accurately identify patients at risk for early recurrence, leading to high healthcare costs and suboptimal treatment decisions, as only about 20% of patients qualify for upfront surgery, with 50% experiencing early recurrence despite adjuvant chemotherapy.

Innovation Solution

A low-cost, high-throughput ATAC-array targeting differentially accessible chromatin regions is used to predict disease-free survival by assessing chromatin accessibility, supplemented with transcription factor expression and nuclear localization data, allowing for personalized treatment decisions and stratification for epigenetic therapies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If traditional treatment protocols are used for PDAC, then treatment decisions can be made based on standard guidelines, but the ability to identify patients at risk for early recurrence is insufficient

Engineering Contradiction:

Improveprediction accuracy of disease-free survivalVSAvoidlack of patient stratification information

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent segments patients into different risk categories (high-risk, intermediate-risk, low-risk) based on chromatin accessibility profiles. By dividing the patient population into distinct groups with different epigenetic signatures, the system enables personalized treatment decisions and improves prediction accuracy for disease-free survival outcomes.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent performs preliminary assessment of chromatin accessibility patterns before treatment initiation to predict disease-free survival outcomes. By evaluating epigenetic features in advance, the system identifies patients at risk for early recurrence prior to starting treatment, allowing for proactive intervention and personalized therapy selection.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If upfront surgery is performed for resectable PDAC, then complete resection can be achieved, but 50% of patients experience early recurrence within the first year

Engineering Contradiction:

Improvedisease-free survival durationVSAvoidearly recurrence risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses chromatin accessibility profiling to provide feedback about a patient's recurrence risk before surgery. By assessing epigenetic features and comparing them against reference patterns, the system generates predictive feedback that guides treatment decisions, allowing patients to be stratified into different risk groups with appropriate follow-up and intervention strategies.

Inventive Principle:

Principle #23Feedback

3Quantity of substance

If adjuvant chemotherapy is administered after surgery, then treatment coverage is improved, but it cannot prevent recurrence in 30-40% of patients within 2-5 years

Engineering Contradiction:

Improvetreatment coverageVSAvoidlong-term disease-free survival

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies local quality by tailoring treatment strategies to specific patient subgroups based on their chromatin accessibility profiles. Different patient groups with distinct epigenetic signatures receive customized treatment recommendations, allowing for optimized therapy selection that addresses the specific biological characteristics of each patient's tumor.

Inventive Principle:

Principle #3Local quality

4Adaptability or versatility

If personalized treatment decisions are made based on chromatin accessibility, then treatment precision is improved, but the complexity of assessment increases

Engineering Contradiction:

Improvepersonalization of treatmentVSAvoidassessment complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent replaces complex multi-parameter clinical assessment with a focused epigenetic profiling approach. By substituting traditional clinical evaluation with chromatin accessibility measurement, the system simplifies the assessment process while enabling more precise patient stratification and personalized treatment decisions.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ATAC-array provides accurate prediction of early recurrence risk, enabling informed decisions on surgical versus neoadjuvant therapy and personalized epigenetic treatment strategies, reducing recurrence risk and healthcare costs.

Implementation Method 1

a hybridization-based technology to detect chromatin accessibility

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

Assay for Transposase-Accessible Chromatin (ATAC)

Methodology Applied

Scientific EffectChromatin accessibility:

Data Source

PatentUS12529091B2ATAC-array for prediction of disease-free survival in pancreatic cancer

Publication Date: 2026.01.20 TRUSTEES OF DARTMOUTH COLLEGE THE

AI summary

The present disclosure relates to an array-based assay for transposase-accessible chromatin and prognostic molecular markers of treatment-resistant/early recurrent cancer. The present disclosure also relates to predicting an outcome, such as duration of disease-free survival, in a cancer patient.